Baloxavir marboxil oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulation of baloxavir marboxil.
Drugs List
Therapeutic Indications
Uses
Influenza - treatment of symptoms
Post-exposure prophylaxis of influenza
Dosage
Baloxavir marboxil should be used in accordance with official recommendations.
A single dose of baloxavir marboxil should be taken as soon as possible within 48 hours of symptom onset. In case of post-exposure prophylaxis of influenza, within 48 hours following close contact with an individual known or suspected to have influenza.
There is no clinical data on the use of a repeat dose of baloxavir marboxil in any one influenza season.
Adults
Adults weighing 80kg or more.
Single dose of 80mg (2 x 40mg tablets).
Adults weighing less than 80kg.
Single dose of 40mg (2 x 20mg tablets).
Children
Children 12 and over, weighing 80kg or more.
Single dose of 80mg (2 x 40mg tablets).
Children under 12, weighing less than 80kg.
Single dose of 40mg (2 x 20mg tablets).
Contraindications
Children under 12 years
Breastfeeding
Galactosaemia
Pregnancy
Severe hepatic impairment
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Lactose intolerance
Contains lactose
Advise patient not to self medicate with antacids or acid suppressants
Advise patient to avoid magnesium-containing laxatives
Baloxavir marboxil should not be taken with products that contain polyvalent cations such as laxatives, antacids or oral supplements containing iron, zinc, selenium, calcium or magnesium in order to avoid a decrease in plasma concentrations of the drug.
Pregnancy and Lactation
Pregnancy
Baloxavir marboxil is contraindicated during pregnancy.
The manufacturer recommends that it is preferable to avoid the use of baloxavir marboxil during pregnancy. At the time of writing there is limited data regarding the use of baloxavir marboxil during pregnancy. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.
Lactation
Baloxavir marboxil is contraindicated during breastfeeding.
The manufacturer advises that the patient either discontinues baloxavir marboxil or discontinues breastfeeding. At the time of writing, it is unknown whether baloxavir marboxil or baloxavir are excreted in human breast milk. Studies in animals have shown that baloxavir marboxil and its metabolites are secreted in the milk of lactating rats. A risk to newborns/infants cannot be excluded.
Side Effects
Anaphylactic reaction
Anaphylaxis
Angioedema
Hypersensitivity reactions
Urticaria
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: December 2021
Reference Sources
Summary of Product Characteristics: Xofluza 40mg film coated tablets. Roche Products Limited. Revised June 2021.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.